Correction: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells.

The authors report that there is a mistake in the representative picture of Fig. 4D (top row: PC3-miR1260b inh-0h) in the original version. The correct version of Fig. 4 with the original pictures for both PC3 miR-NC inh-0h and PC3-miR1260b inh-0h are provided below.

Correction to: British Journal of Cancer 110, 1645–1654 (2014); 10.1038/bjc.2014.48; published online 6 February 2014

The authors report that there is a mistake in the representative picture of Fig. 4D (top row: PC3-miR1260b inh-0h) in the original version. The correct version of Fig. 4 with the original pictures for both PC3 miR-NC inh-0h and PC3-miR1260b inh-0h are provided below.

Fig. 4

Effect of miR-1260b knockdown on prostate cancer cells (PC-3, DU-145). Two prostate cancer cell lines (PC-3 and DU-145) were transiently transfected with either miR-1260b inhibitor or miR-negative control (miR-NC inhibitor). a Relative miR-1260b expression (miR-NC inhibitor or miR-1260b inhibitor transfected PC cells), b cell viability assay (miR-NC inhibitor or miR-1260b inhibitor transfected PC cells), c invasion assay, d wound healing assay (16–17 h). e Apoptosis assay, f cell cycle analysis, g TCF reporter assay. Error bars represent ±s.d